Investor Summary
Fund Strategy
FUND PERFORMANCE AS OF 30th September 2025
| ANNUALIZED SINCE INCEPTION | QUARTERLY | YTD |
|---|---|---|
| 10.7% | - | 8.2% |
| ANNUALIZED SINCE INCEPTION | QUARTERLY | YTD |
|---|---|---|
| 10.7% | - | 8.2% |
Lorem ipsum dolor sit amet, consectetur adipiscing elit.
Lorem ipsum dolor sit amet, consectetur adipiscing elit.
Lorem ipsum dolor sit amet, consectetur adipiscing elit.
| Date | Letter | Tickers | Keywords | Pitches | Quick Takes |
|---|---|---|---|---|---|
| Oct 22 2025 | 2025 Q3 | ALC, COO, FI, GOOG, KMX, ORCL, PM, PPG, RYAN, TSLA, WAT | AI, Compounding, Health Care, Quality, valuation |
ORCL ALC COO RYAN WAT ORCL ALC COO RYAN WAT |
Kovitz highlights market concentration in AI and mega-cap technology stocks while maintaining a valuation-disciplined focus on quality compounders. The strategy increased exposure to healthcare and insurance names like Alcon and Ryan Specialty after taking profits in Oracle. The team stresses long-term fundamentals and risk discipline amid elevated valuations and AI euphoria. |
| Jul 15 2025 | 2025 Q2 | ADI, BDX, FI, FND, HAS, META, MSFT, MSI, ORCL, TMO | Balance Sheets, Capital discipline, Competitive Advantage, Concentration, Quality | - | The letter focuses on owning a concentrated portfolio of high-quality businesses with strong balance sheets and durable competitive advantages. Management prioritizes downside protection, conservative capital structures, and long holding periods. Patience and business fundamentals are emphasized over market timing. |
| Apr 21 2025 | 2025 Q1 | ADBE, ADI, AMZN, ANET, ASHTY, BRK/A, DGE LN, GOOG, ICE, JPM, MSFT, PM | - | - | |
| Jan 21 2025 | 2024 Q4 | AMAT, AMD, AMTM, AMZN, CRM, GOOG, LVS, TMO | - | - | |
| Oct 17 2024 | 2024 Q3 | AAPL, ADI, AMAT, AXP, BRK/A, DLTR, FI, GM, HAS, J, JPM, KEYS, MSI, PCAR, SCHW, SPOT, UNH | - | - | |
| Jul 16 2024 | 2024 Q2 | BDX, DGE LN, ICE, KMX, MSI, PPG | - | - | |
| Apr 12 2024 | 2024 Q1 | AON, BDX, CHTR, GIL, GOOG, JPM, KMX, META, ORCL, PCAR, PPG, SPLK, SPOT | - | - | |
| Jan 16 2024 | 2023 Q4 | AAPL, ADSK, BDX, DGE LN, DLTR, GIL, GM, GOOG, LOW, PCAR | - | - | |
| Oct 17 2023 | 2023 Q3 | AXP, BX, DGE LN, DIS, EXPE, HAS, KEYS, KMX, PM | - | - | |
| Jul 17 2023 | 2023 Q2 | AAPL, DGE LN, DLTR, GDDY, JPM, MSI, SCHW | - | - | |
| Apr 18 2023 | 2023 Q1 | ANET, AXP, GOOG, J, KEYS, LVS, META, PM, PPG, PWR | - | - | |
| Jan 1 2023 | 2022 Q4 | AMZN, CHTR, KMX, LOW, LVS, MSI | - | - | |
| Oct 17 2022 | 2022 Q3 | ADI, BKNG, J, JPM, KMX, NTRS, PWR | - | - | |
| Jul 21 2022 | 2022 Q2 | ADI, ANET, C, CHTR, CVET, DLTR, ICE, KMX, PCAR, PWR | - | - | |
| Apr 15 2022 | 2022 Q1 | HAYW, J, SPOT | - | - |
| QUARTER | THEMES | TAGS |
|---|---|---|
| 2025 Q3 |
AIAI has been integrated into RGA's research process through tools like NotebookLM, Gems in Gemini, and Claude Code. The firm views AI as a force multiplier for human judgment rather than a replacement, emphasizing the Kasparov Law principle. They believe the market narrative around AI displacement is swinging to unhelpful extremes, creating investment opportunities. |
Machine Learning Automation Software Productivity Innovation |
HealthcareHealthcare was the strongest relative contributor in the quarter with holdings increasing nearly +16% compared to benchmark returns of roughly +12%. Exact Sciences was acquired for a significant premium by Abbott Laboratories resulting in an +86% return, while other strong performers included Tarsus Pharmaceuticals, Glaukos following approval of a new product, Penumbra, and Repligen driven by strong earnings results. |
M&A Product Approval Earnings Biotech | |
QualityThe company emphasizes investing in businesses with excellent economics, durable competitive advantages, and high-integrity management. This quality focus is evident in concentrated equity holdings and operating business acquisitions. |
Durable Advantages Management Quality Economic Moats Competitive Position | |
| 2025 Q2 |
QualityThe company emphasizes investing in businesses with excellent economics, durable competitive advantages, and high-integrity management. This quality focus is evident in concentrated equity holdings and operating business acquisitions. |
Durable Advantages Management Quality Economic Moats Competitive Position |
| Date | Pitch Type | Author | Ticker | Company | Industry | Sub Industry | Bull / Bear | Exchange | Keywords | Action |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct 22, 2025 | Fund Letters | Matt Hayner | ORCL | Oracle Corporation | Information Technology | System Software | Bear | NYSE | AI, backlog, cloud, concentration risk, Contracts, risk management, valuation | Login |
| Oct 22, 2025 | Fund Letters | Matt Hayner | ALC | Alcon Inc. | Health Care | Health Care Equipment | Bull | Swiss Exchange | Demographics, growth, innovation, lenses, Ophthalmology, Procedures, R&D | Login |
| Oct 22, 2025 | Fund Letters | Matt Hayner | COO | Cooper Companies Inc. | Health Care | Health Care Supplies | Bull | NYSE | cashflow, Contacts, healthcare, lenses, Margins, oligopoly, valuation | Login |
| Oct 22, 2025 | Fund Letters | Matt Hayner | RYAN | Ryan Specialty Holdings Inc. | Financials | Insurance Brokers | Bull | NYSE | Cyclicality, growth, Insurance, Margins, specialty, underwriting, valuation | Login |
| Oct 22, 2025 | Fund Letters | Matt Hayner | WAT | Waters Corporation | Health Care | Life Sciences Tools & Services | Bull | NYSE | acquisition, Analytical instruments, Biotech, diagnostics, EPS growth, recurring revenue, synergy | Login |
| Oct 22, 2025 | Fund Letters | Matt Hayner | ORCL | Oracle Corporation | Information Technology | System Software | Bear | NYSE | AI, backlog, cloud, concentration risk, Contracts, risk management, valuation | Login |
| Oct 22, 2025 | Fund Letters | Matt Hayner | ALC | Alcon Inc. | Health Care | Health Care Equipment | Bull | Swiss Exchange | Demographics, growth, innovation, lenses, Ophthalmology, Procedures, R&D | Login |
| Oct 22, 2025 | Fund Letters | Matt Hayner | COO | Cooper Companies Inc. | Health Care | Health Care Supplies | Bull | NYSE | cashflow, Contacts, healthcare, lenses, Margins, oligopoly, valuation | Login |
| Oct 22, 2025 | Fund Letters | Matt Hayner | RYAN | Ryan Specialty Holdings Inc. | Financials | Insurance Brokers | Bull | NYSE | Cyclicality, growth, Insurance, Margins, specialty, underwriting, valuation | Login |
| Oct 22, 2025 | Fund Letters | Matt Hayner | WAT | Waters Corporation | Health Care | Life Sciences Tools & Services | Bull | NYSE | acquisition, Analytical instruments, Biotech, diagnostics, EPS growth, recurring revenue, synergy | Login |
| TICKER | COMMENTARY |
|---|---|
| COO | Cooper was a top contributor during the quarter after reporting good operating results and announcing several shareholder-friendly developments. In terms of operating results, the company demonstrated progress in alleviating supply constraints for its premium daily silicone hydrogel contact lenses, announced new private label contract wins in the U.S. and Europe, and delivered innovation in myopia control and multifocal lens platforms. |
| FI | Notable detractors from performance came from Fiserv (-43bps absolute and -39bps relative) |
| GOOG | From the moment OpenAI hit the scene with ChatGPT 3.5 in the Fall of 2022, Google was a perceived loser and thousands of pontificators warned about the end of search. Fast forward three years and this was Google Search's fastest quarter of revenue growth since Q1 2022, when the reopening and pandemic were still considerable drivers of results. In parallel with the Search re-acceleration, Google has also emerged as a leader in AI itself. This combination has been potent for Google's stock and could not have opened on Search alone, given the terminal value fears. |
| KMX | Over the past five years, CarMax's shares declined by 62%, while Carvana's shares rose by 73%, leaving CarMax's market capitalization at roughly one-tenth of Carvana's today. |
| ORCL | Investor enthusiasm for Oracle's stock in calendar year 2025 was initially driven by several multi-billion-dollar contracts it signed with leading AI companies, including OpenAI and Meta. However, in Q4 sentiment for ORCL's growth prospects shifted to skepticism, as investors began to scrutinize the return profile of the substantial capital investments required to support the approximately $500 billion of contracts signed by Oracle. Given the widening range of potential outcomes associated with Oracle's elevated capital needs, we reduced our position in ORCL during Q4. |
| PM | New positions were initiated in Philip Morris |
| PPG | coatings company PPG |
| RYAN | Ryan Specialty Holdings, Inc. is a commercial excess and surplus insurance broker with a delegated authority business. The company was founded by Pat Ryan in 2010. Pat Ryan is one of the insurance industry's crucial pioneers, having also founded Aon where he served as the CEO and Chairman for 41 years. The excess and surplus market has grown at an 11% CAGR while the admitted market has grown at a 4% CAGR over the last 25 years. The portion of Ryan Specialty's business exposed to commercial property is entering a soft pricing cycle, which has pushed the stock well below intrinsic value. |
| TSLA | Under the previous system, companies that produced only electric vehicles—most notably Tesla—generated large quantities of credits that could then be sold to manufacturers falling short of their EV production targets, allowing them to avoid regulatory penalties. |
| WAT | Waters reported solid results supported by growth in Asia, and we increased the position following its acquisition of Becton Dickinson's biosciences and diagnostics business |
| Ticker | Put/Call | Amount Bought | Shares Bought | % Change | Weight % |
|---|---|---|---|---|---|
| No Recent Buys Data | |||||
| Ticker | Put/Call | Amount Sold | Shares Sold | % Change | Weight % | Status |
|---|---|---|---|---|---|---|
| No Recent Sells Data | ||||||
| Industry | Prev Quarter % | Current Quarter % | Change |
|---|---|---|---|
| No industry data available | |||